Unresectable Metastatic Colorectal Cancer

Oncology

Prevalence

135.0 / 100K

Incidence

36.0 / 100K/yr

12 drugs in development·5 companies·1 clinical trial

Drug Pipeline by Phase

Phase 2(2)

Drug	Company
FOLFOX	ENANTA PHARMACEUTICALS INC (ENTA)
Fosifloxuridine Nafalbenamide	IGM Biosciences, Inc. (IGMS)

Phase 1(10)

Drug	Company
FOLFIRI	REGENXBIO Inc. (RGNX)
FOLFIRI	ENANTA PHARMACEUTICALS INC (ENTA)
FOLFIRI	BridgeBio Oncology Therapeutics, Inc. (BBOT)
FOLFOX	BridgeBio Oncology Therapeutics, Inc. (BBOT)
FOLFOX	REGENXBIO Inc. (RGNX)
JNJ-89402638	Merus N.V. (MRUS)
JNJ-89402638	ENANTA PHARMACEUTICALS INC (ENTA)
JNJ-89402638	REGENXBIO Inc. (RGNX)
JNJ-89402638	IGM Biosciences, Inc. (IGMS)
JNJ-89402638	BridgeBio Oncology Therapeutics, Inc. (BBOT)

BioSniper tracks 12 drugs in development for Unresectable Metastatic Colorectal Cancer across 5 companies.

There are 1 clinical trial targeting Unresectable Metastatic Colorectal Cancer tracked by BioSniper.

The estimated prevalence of Unresectable Metastatic Colorectal Cancer is approximately 135.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.